CFRA, Equity and Fund Research
Sel Hardy joined CFRA in October 2019 and is a fundamental equity research analyst covering several segments within the healthcare sector such as pharmaceuticals, managed health care, life sciences tools and services, health care distributors, and services. Prior to joining CFRA, she worked in equity and fixed-income research at Is Investment, the leading investment bank in Turkey. Ms. Hardy analyzed stocks and corporate bonds traded on the Istanbul Stock Exchange.
Centene Corporation (CNC) carries CFRA's highest investment recommendation of 5-STARS, or Strong Buy, notes analyst Sel Hardy in CFRA Research's flagship newsletter, The Outlook.
Zoetis (ZTS) is among the top global companies in the discovery, development, manufacture, and marketing of animal health medicines and vaccines, with a focus on both livestock and companion animals, explains equity analyst Sel Hardy in CFRA Research's The Outlook.
With more than 6 million confirmed Covid-19 cases worldwide and the number increasing daily, the race for a Covid-19 vaccine is moving at full speed, asserts Sel Hardy, equity analyst at CFRA Research's flagship newsletter, The Outlook.